Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase.
Piritrexim (PTX), 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidin e, formerly called BW 301U, is a potent small-molecule inhibitor of dihydrofolate reductase (DHFR) that enters cells rapidly by passive diffusion and thus does not depend upon the transport-mediated uptake that can limit cell entry of methotrexate (MTX). PTX is as active as MTX in inhibiting DHFR and mammalian cell growth. In vivo, PTX is active against Walker 256, L1210, P388, Sarcoma 180, and Ehrlich ascites tumors. After iv administration of [14C]PTX to rats, the elimination profile of intact drug from plasma was first order with a half-life (t1/2) of 38 minutes. PTX penetrates extensively into tissues and its tissue:plasma concentration ratios are generally 10-fold higher than those reported for MTX. When administered systemically, PTX inhibits the DHFR-dependent conversion of sepiapterin or 7,8-dihydrobiopterin (BH2) to tetrahydrobiopterin (BH4), demonstrating that PTX enters brain at pharmacologically relevant concentrations. Pharmacokinetic studies in the dog indicated a mean plasma t1/2 (after iv dose) of 2.15 hours, total body clearance of 0.625 liters/hr/kg and steady-state volume of distribution of 1.82 liters/kg; the absolute bioavailability was 0.64. Toxicologic studies were conducted in rats and dogs that received daily doses for 1, 5, or 90 days. In dogs, oral doses of 480 (single dose), 25 (5 daily doses), and 2.5 mg/kg (90 daily doses) were lethal, whereas 240 (single dose), 2.5 (5 daily doses), and 0.5 mg/kg (90 daily doses) produced reversible alterations in clinical toxicity and histopathologic parameters. The lethal toxicity of PTX in dogs given 25 mg/kg/day for 5 days is prevented by oral calcium leucovorin rescue with either 0.75 or 3.0 mg/kg every hour for 4 hours on any of the 5 treatment days. The general pharmacologic profile indicates that PTX should be free of CNS, cardiovascular, and respiratory side effects at clinically useful doses.
Sigel
C W
CW
Wellcome Research Laboratories, Research Triangle Park, NC 27709.
Macklin
A W
AW
Woolley
J L
JL
Johnson
N W
NW
Collier
M A
MA
Blum
M R
MR
Clendeninn
N J
NJ
Everitt
B J
BJ
Grebe
G
G
Mackars
A
A
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D004285:Dogs; D005493:Folic Acid Antagonists; D006321:Heart / Q000187:drug effects; D008657:Metabolic Clearance Rate; D008727:Methotrexate / Q000493:pharmacokinetics; D051379:Mice; D009130:Muscle, Smooth / Q000187:drug effects; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011743:Pyrimidines / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity; D051381:Rats; D012995:Solubility; D014018:Tissue Distribution; D014407:Tumor Cells, Cultured
D005493:Folic Acid Antagonists; D011743:Pyrimidines; C024530:piritrexim; D008727:Methotrexate